Parkinson's disease: Cogentin with Sinemet, a better response

Area of Science:

• Neurology
• Pharmacology

Background:

• Idiopathic Parkinson disease (IPD) is a progressive neurodegenerative disorder.
• Levodopa-carbidopa (Sinemet) is a primary treatment, but symptom management can be challenging.
• Anticholinergic agents are sometimes used, but their efficacy in conjunction with Sinemet requires clear evidence.

Purpose of the Study:

• To evaluate the clinical efficacy of benztropine mesylate (Cogentin) as an adjuvant therapy in patients with mild to moderate IPD already receiving Sinemet.
• To assess the impact of adding benztropine mesylate to established Sinemet treatment on motor and functional symptoms.

Main Methods:

• A randomized, placebo-controlled, double-blind, cross-over study design was employed.
• Twenty-nine patients with mild to moderate IPD on stable Sinemet dosages participated.
• Evaluations included neurologist and patient global assessments, and quantitative measures of rigidity, finger tapping, and activities of daily living.

Main Results:

• Sinemet plus benztropine mesylate demonstrated significantly greater improvement compared to Sinemet plus placebo, based on both neurologist and patient global assessments.
• Statistically significant, albeit small, improvements were observed in rigidity, finger tapping speed, and activities of daily living.
• No significant adverse side effects were reported during the study.

Conclusions:

• Benztropine mesylate is an effective adjuvant therapy for mild to moderate idiopathic Parkinson disease when added to levodopa-carbidopa.
• The addition of benztropine mesylate offers incremental benefits in motor function and daily activities with a favorable safety profile.
• A majority of patients opted to continue benztropine mesylate post-study, indicating perceived clinical utility.